Viatris (VTRS)

The company’s business spans commoditized generic drugs, more complex formulations, biosimilars, and branded products whose patent protection has expired or matured. Its legacy portfolio includes widely recognized medicines such as Lipitor, Norvasc, Lyrica, and Viagra, while its generics and biosimilars operations help supply lower-cost alternatives in major therapeutic categories. Viatris serves pharmacies, wholesalers, governments, health systems, and other healthcare customers, making scale, manufacturing reliability, regulation, and distribution central to its competitive position.

Although its catalog covers many treatment areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as key fields for future development and investment. The company’s role in the healthcare system is largely tied to medicine access: producing and distributing established therapies at global scale while selectively pursuing higher-value products in complex generics and biosimilars. For investors, Viatris is positioned less as a high-risk drug discovery company and more as a diversified manufacturer and marketer of mature pharmaceuticals, with cash flow, portfolio management, debt reduction, and product pipeline execution important drivers of performance.